Abion

Abion ROA

The Return on Assets (ROA) of Abion (203400.KQ) as of Oct 22, 2026 is -36.07 %. In the previous year, Return on Assets (ROA) was -68.01 % — a change of -46.97% (higher).

ROA

-36.07 %

YoY

-46.97%

Last updated:

In 2025, Abion's return on assets (ROA) was -36.07 %, a -46.97% increase from the -68.01 % ROA in the previous year.

The Abion ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-108.00 KRW
Jan 1, 2019
-149.76 KRW
Jan 1, 2020
-78.36 KRW
Jan 1, 2021
-121.61 KRW
Jan 1, 2022
-82.53 KRW
Jan 1, 2023
-65.39 KRW
Jan 1, 2024
-68.01 KRW
Jan 1, 2025
-36.07 KRW
The Abion ROA history
YEARROAYoY
-36.07 %-46.97%
-68.01 %+4.02%
-65.39 %-20.77%
-82.53 %-32.13%
-121.61 %+55.19%
-78.36 %-47.68%
-149.76 %+38.66%
-108.00 %-4.64%
-113.26 %+90.98%
-59.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Abion Stock analysis

What does Abion do? ABION, Inc. generates revenue through its Product segment, which sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment offers histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services to clients in the biopharmaceutical industry. The Research segment focuses on developing drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics, with potential future commercialization. The company's business model relies on these four segments to serve biopharmaceutical companies seeking innovative diagnostic tools and therapeutic solutions. The Product segment targets biopharmaceutical firms requiring laboratory supplies for research and diagnostics. The CRO Service segment caters to clients needing specialized analytical services for drug development. The Research segment develops proprietary therapeutics that may be licensed or sold to partners in the pharmaceutical sector. ABION's revenue streams are derived from direct sales of reagents and services, as well as potential future licensing agreements from its research pipeline. ABION's business model integrates product sales, CRO services, and R&D activities to address multiple needs within the biopharmaceutical value chain. The company's diagnostic reagents and research reagents are sold directly to laboratories and research institutions. The CRO services are contracted by biopharmaceutical companies for specialized testing during drug development. The Research segment's focus on protein, nucleic acid, and antibody therapeutics positions ABION to develop novel treatments for incurable diseases, with commercialization opportunities through partnerships or direct sales. Abion is one of the most popular companies on Eulerpool.

ROA Details

Understanding Abion's Return on Assets (ROA)

Abion's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Abion's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Abion's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Abion’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Abion stock

Return on Assets (ROA) of Abion is -36.07 % in 2025.

Return on Assets (ROA) of Abion changed from -68.01 % to -36.07 %, representing a -46.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Abion since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Abion with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Abion

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Abion